# US 2019/0376880 A1 · Device And Methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376880 A1
- Document ID: US20190376880A1
- Status: Published application
- Kind: A1
- Application number: 16/372,264
- Filed: 2019-04-01
- Published: 2019-12-12
- Earliest claimed: 2013-02-04
- Assignees: Epona Biotech Ltd
- Applicants: Epona Biotech Ltd
- Inventors: Heinrich Anhold; Ruth Candon; Di-Sien Chan
- Web page: https://patentgrep.com/patent/US20190376880A1

## CPC

- G01N 1/38: Diluting, dispersing or mixing samples
- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- B01L 3/0203: {Burettes, i.e. for withdrawing and redistributing liquids through different conduits}
- B01L 3/0241: {Drop counters; Drop formers}
- G01N 33/543: with an insoluble carrier for immobilising immunochemicals
- G01N 33/54388: {based on lateral flow}
- G01N 33/54389: {with bidirectional or multidirectional lateral flow, e.g. wherein the sample flows from a single, common sample application point into multiple strips, lanes or zones}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- B01L 2200/025: Align devices or objects to ensure defined positions relative to each other
- B01L 2200/026: Fluid interfacing between devices or objects, e.g. connectors, inlet details
- B01L 2200/0689: Sealing
- B01L 2300/0838: Capillaries
- B01L 2300/161: Control and use of surface tension forces, e.g. hydrophobic, hydrophilic
- G01N 2001/383: {collecting and diluting in a flow of liquid}
- G01N 2333/75: Fibrin; Fibrinogen
- G01N 2333/775: Apolipopeptides
- G01N 2333/91188: transferring nitrogenous groups (2.6)
- G01N 2333/9123: with a nitrogenous group as acceptor (2.7.3), e.g. histidine kinases
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- G01N 2800/40: Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates generally to methods and materials pertaining to assays, for example immunoassays, for biomarkers in body fluids e.g. blood. The invention also relates to diagnostic or screening methods for infections, and methods of differentiating between infectious and non-infectious conditions in mammals, particularly equines, for monitoring response to anti-infective/antibiotic therapy. The invention further relates to a test fluid collection system adapted to permit dilution and analysis of the collected test fluid. The invention further relates to monitoring exertional rhabdomyolysis in equines, and assay devices for all these things.

## Claims

### Claim at position 1

1-79. (canceled)

### Claim at position 2

8-101. (canceled)

### Claim 80

A method of diluting a metred quantity of a test fluid for analysis, the method comprising:
i) contacting a collection tip coupled to a housing with a sample of the test fluid to collect the metred quantity of test fluid into a collection port within the housing;
ii) inserting the housing into an opening of a liquid container to form a seal fit between said opening and said housing; and
iii) agitating the container such that a metred quantity of test fluid is extracted from the collection port into liquid within the liquid container.

### Claim 81 (depends on 80)

The method of claim 80 further comprising dispensing a diluted test fluid for analysis, the dispensing comprising:
inverting or reducing the volume of the liquid container such that the diluted test fluid is forced through a dispensing inlet, along to a dispensing channel and out of a dispensing nozzle defined by structures of the housing.

### Claim 82 (depends on 81)

The method as claimed in claim 81, wherein the diluted test fluid is dispensed as drops from the dispensing nozzle.

### Claim 83 (depends on 81)

The method as claimed in claim 81 further comprising:
i) dispensing the diluted test fluid into an analytical device; and
ii) assessing a presence or amount of said one or more analytes with said device.

### Claim 84 (depends on 83)

The method as claimed in claim 83, wherein the device is a lateral flow device (LFD) device.

### Claim 85 (depends on 48)

The system as claimed in claim 48, wherein the test fluid is a body fluid.

### Claim 102 (depends on 81)

The method as claimed in claim 81, further comprising:
diluting the test fluid by a pre-determined amount prior to the analysis.
